Denali Therapeutics Inc. Earnings Per Share, Basic and Diluted
Denali Therapeutics Inc. (DNLI) reported Earnings Per Share, Basic and Diluted of -$0.54 per share for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2020-11-05
- Denali Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.54.
- Denali Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.56.
- Denali Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2020-03-31 was -$0.55.
- Denali Therapeutics Inc. earnings per share, basic and diluted for the quarter ending 2019-12-31 was -$0.56, a 168.12% decline year-over-year.
- Denali Therapeutics Inc. earnings per share, basic and diluted for fiscal 2019 was -$2.07.
- Denali Therapeutics Inc. earnings per share, basic and diluted for fiscal 2018 was -$0.39.
- Denali Therapeutics Inc. earnings per share, basic and diluted for fiscal 2017 was -$5.89.
- Denali Therapeutics Inc. earnings per share, basic and diluted for fiscal 2016 was -$13.49.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$0.54 10-Q · filed 2020-11-05 | -$1.10 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.65 10-Q · filed 2020-11-05 | -$2.21 derived: net income ÷ weighted average shares · filed 2021-11-04 |
| 2020-06-30 | -$0.56 10-Q · filed 2020-08-07 | -$1.11 10-Q · filed 2020-08-07 | -$1.67 derived: net income ÷ weighted average shares · filed 2021-08-04 | -$2.16 derived: net income ÷ weighted average shares · filed 2021-08-04 |
| 2020-03-31 | -$0.55 10-Q · filed 2020-05-07 | -$1.12 derived: net income ÷ weighted average shares · filed 2021-05-05 | -$1.60 derived: net income ÷ weighted average shares · filed 2021-05-05 | -$2.21 derived: net income ÷ weighted average shares · filed 2021-05-05 |
| 2019-12-31 | -$0.56 10-K · filed 2020-02-27 | -$1.04 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$1.66 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$2.07 10-K · filed 2020-02-27 |
| 2019-09-30 | -$0.48 10-Q · filed 2020-11-05 | -$1.09 derived: net income ÷ weighted average shares · filed 2020-11-05 | -$1.50 10-Q · filed 2020-11-05 | -$0.69 derived: net income ÷ weighted average shares · filed 2020-11-05 |
| 2019-06-30 | -$0.61 10-Q · filed 2020-08-07 | -$1.02 10-Q · filed 2020-08-07 | -$0.21 derived: net income ÷ weighted average shares · filed 2020-08-07 | -$0.58 derived: net income ÷ weighted average shares · filed 2020-08-07 |
| 2019-03-31 | -$0.41 10-Q · filed 2020-05-07 | $0.41 derived: net income ÷ weighted average shares · filed 2020-05-07 | $0.03 derived: net income ÷ weighted average shares · filed 2020-05-07 | -$0.55 derived: net income ÷ weighted average shares · filed 2020-05-07 |
| 2018-12-31 | $0.82 derived: net income ÷ weighted average shares · filed 2020-02-27 | $0.45 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$0.13 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$0.39 10-K · filed 2020-02-27 |
| 2018-09-30 | -$0.38 10-Q · filed 2019-11-06 | -$0.97 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$1.24 10-Q · filed 2019-11-06 | -$1.78 derived: net income ÷ weighted average shares · filed 2020-02-27 |
| 2018-06-30 | -$0.59 10-Q · filed 2019-08-06 | -$0.86 10-Q · filed 2019-08-06 | -$1.42 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$2.20 derived: net income ÷ weighted average shares · filed 2020-02-27 |
| 2018-03-31 | -$0.26 10-Q · filed 2019-05-08 | -$0.77 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$1.57 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$2.58 derived: net income ÷ weighted average shares · filed 2020-02-27 |
| 2017-12-31 | -$0.74 10-K · filed 2019-03-12 | -$2.17 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$3.95 derived: net income ÷ weighted average shares · filed 2020-02-27 | -$5.89 10-K · filed 2020-02-27 |
| 2017-09-30 | -$2.14 10-K · filed 2019-03-12 | -$4.42 derived: net income ÷ weighted average shares · filed 2019-03-12 | -$6.77 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$2.29 10-K · filed 2019-03-12 | -$4.65 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$2.36 10-K · filed 2019-03-12 | |||
| 2016-12-31 | -$13.49 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |